McKesson: Strong Momentum Masks Legal & Valuation Risks – Retain Caution

What happened

McKesson's recent strength is driven by robust oncology, GLP-1, and RxTS growth, pushing earnings and the stock to new highs. However, DeepValue analysis reveals that growth is heavily acquisition-aided and boosted by one-time gains, while organic volumes normalize. The revived $2.5B West Virginia opioid suit and $5.7B in existing liabilities constrain financial flexibility, despite strong cash flows. At ~21x forward EBITDA, the stock prices in sustained 13-16% EPS compounding, leaving little margin for error if segment growth decelerates or legal costs escalate. The risk-reward skews unfavorable, supporting a trim into strength with a re-entry target near $720.

Implication

McKesson's franchise quality and specialty momentum are real, but the current price offers inadequate compensation for regulatory and litigation risks. Investors should reduce exposure and wait for either clearer resolution on opioid liabilities or a pullback below $720 before re-engaging. The strong run has already discounted optimistic assumptions, and any disappointment could lead to multiple compression.

Thesis delta

The article's 'retain' narrative underestimates the height of valuation and the resurfacing of a material opioid lawsuit. The DeepValue report shifts the view from a straightforward growth compounder to a story where execution risk and legal tail-risk are increasingly binding, warranting a more cautious stance and lower target prices.